Zobrazeno 1 - 10
of 173
pro vyhledávání: '"John P Perentesis"'
Autor:
Michael T Williams, Chiho Sugimoto, Samantha L Regan, Emily M Pitzer, Adam L Fritz, Mathieu Sertorio, Anthony E Mascia, Ralph E Vatner, John P Perentesis, Charles V Vorhees
Publikováno v:
PLoS ONE, Vol 17, Iss 9, p e0274007 (2022)
Recent studies suggest that ultra-high dose rates of proton radiation (>40 Gy/s; FLASH) confer less toxicity to exposed healthy tissue and reduce cognitive decline compared with conventional radiation dose rates (~1 Gy/s), but further preclinical dat
Externí odkaz:
https://doaj.org/article/8cca211bfd4841748d9af0addd081e91
Autor:
Mark Wunderlich, Nicole Manning, Christina Sexton, Anthony Sabulski, Luke Byerly, Eric O'Brien, John P Perentesis, Benjamin Mizukawa, James C Mulloy
Publikováno v:
PLoS ONE, Vol 14, Iss 11, p e0225532 (2019)
We have previously characterized an acute myeloid leukemia (AML) chemotherapy model for SCID-based immune deficient mice (NSG and NSGS), consisting of 5 days of cytarabine (AraC) and 3 days of anthracycline (doxorubicin), to simulate the standard 7+3
Externí odkaz:
https://doaj.org/article/cd47170d50ec4a2e8bcc41f4eec1940c
Autor:
Michael T. Williams, Chiho Sugimoto, Samantha L. Regan, Emily M. Pitzer, Adam L. Fritz, Anthony E. Mascia, Mathieu Sertorio, Ralph E. Vatner, John P. Perentesis, Charles V. Vorhees
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-20 (2020)
Abstract Proton radiotherapy causes less off-target effects than X-rays but is not without effect. To reduce adverse effects of proton radiotherapy, a model of cognitive deficits from conventional proton exposure is needed. We developed a model empha
Externí odkaz:
https://doaj.org/article/5d32edd717014b9596a855396e69d6d1
Autor:
Brigitte C. Widemann, Yao Lu, Denise Reinke, Scott H. Okuno, Christian F. Meyer, Gregory M. Cote, Rashmi Chugh, Mohammed M. Milhem, Angela C. Hirbe, AeRang Kim, Brian Turpin, Joseph G. Pressey, Eva Dombi, Nalini Jayaprakash, Lee J. Helman, Ndidi Onwudiwe, Karen Cichowski, John P. Perentesis
Publikováno v:
Sarcoma, Vol 2019 (2019)
Purpose. There are no known effective medical treatments for refractory MPNST. Inactivation of the NF1 tumor suppressor in MPNST results in upregulation of mTOR (mammalian target of rapamycin) signaling and angiogenesis, which contributes to disease
Externí odkaz:
https://doaj.org/article/401c98540a2a455a8f01beecb09b82fe
Autor:
Nancy Ratner, Shyra J. Miller, Timothy P. Cripe, Eduard Serra, John P. Perentesis, Bruce J. Aronow, Mark G. Qian, Jeffrey A. Ecsedy, Tilat A. Rizvi, Walter J. Jessen, David Eaves, Ami V. Patel
XLS file, 636K, 339 Ras-Driven Genes Differentially Expressed in Mouse or Human Neurofibromas or MPNSTs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71f5425141ed6927525332e8013d5ff4
https://doi.org/10.1158/1078-0432.22446887
https://doi.org/10.1158/1078-0432.22446887
Autor:
Susan M. Blaney, Brenda Weigel, Helen Chen, L. Austin Doyle, Peter J. Houghton, Darcy A. Krueger, Carol A. Mercer, George Thomas, Charlotte Ahern, Joel M. Reid, Alexander A. Vinks, Lars M. Wagner, John P. Perentesis, Maryam Fouladi
Supplemental Figure 1. Graph of IMC-A12 trough serum concentrations versus time.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b985670d0034ef45eca9969c9267b7d
https://doi.org/10.1158/1078-0432.22460369
https://doi.org/10.1158/1078-0432.22460369
Autor:
Nancy Ratner, Shyra J. Miller, Timothy P. Cripe, Eduard Serra, John P. Perentesis, Bruce J. Aronow, Mark G. Qian, Jeffrey A. Ecsedy, Tilat A. Rizvi, Walter J. Jessen, David Eaves, Ami V. Patel
PDF file, 595K, Supplementary Figure S2. Gene Interaction Network of 339 Ras-Driven Genes Differentially Expressed in Mouse or Human Neurofibromas or MPNSTs. Supplementary Figure S3. Dot plot showing qPCR DNA-copy number results for AURKA gene locus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::056ea691842bbebb70cd3203ac227ab3
https://doi.org/10.1158/1078-0432.22446884
https://doi.org/10.1158/1078-0432.22446884
Autor:
Nancy Ratner, Shyra J. Miller, Timothy P. Cripe, Eduard Serra, John P. Perentesis, Bruce J. Aronow, Mark G. Qian, Jeffrey A. Ecsedy, Tilat A. Rizvi, Walter J. Jessen, David Eaves, Ami V. Patel
Purpose: Patients with neurofibromatosis type 1 (NF1) develop malignant peripheral nerve sheath tumors (MPNST), which are often inoperable and do not respond well to current chemotherapies or radiation. The goal of this study was to use comprehensive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d238bf5b44d04c59f24a8f34aec8e20b
https://doi.org/10.1158/1078-0432.c.6520904.v1
https://doi.org/10.1158/1078-0432.c.6520904.v1
Autor:
Susan M. Blaney, Brenda Weigel, Helen Chen, L. Austin Doyle, Peter J. Houghton, Darcy A. Krueger, Carol A. Mercer, George Thomas, Charlotte Ahern, Joel M. Reid, Alexander A. Vinks, Lars M. Wagner, John P. Perentesis, Maryam Fouladi
Supplemental Table 1. IMC-A12 trough serum concentrations during cycle 1 and cycle 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6de4d674d20873bcf36007d1516b395e
https://doi.org/10.1158/1078-0432.22460366
https://doi.org/10.1158/1078-0432.22460366
Autor:
Susan M. Blaney, Brenda Weigel, Helen Chen, L. Austin Doyle, Peter J. Houghton, Darcy A. Krueger, Carol A. Mercer, George Thomas, Charlotte Ahern, Joel M. Reid, Alexander A. Vinks, Lars M. Wagner, John P. Perentesis, Maryam Fouladi
Purpose: To determine the MTD, dose-limiting toxicities (DLT), pharmacokinetics, and biologic effects of cixutumumab administered in combination with temsirolimus to children with refractory solid tumors.Experimental Design: Cixutumumab and temsiroli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df17789d0d1404ac383d00fe6dfb792f
https://doi.org/10.1158/1078-0432.c.6524471.v1
https://doi.org/10.1158/1078-0432.c.6524471.v1